Janus Henderson Group’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.2M | Hold |
23,254
| – | – | ﹤0.01% | 1617 |
|
|
2025
Q4 | $1.16M | Sell |
23,254
-48,472
| -68% | -$2.36M | ﹤0.01% | 1599 |
|
|
2025
Q3 | $3.43M | Buy |
71,726
+48,472
| +208% | +$1.95M | ﹤0.01% | 1076 |
|
|
2025
Q2 | $733K | Hold |
23,254
| – | – | ﹤0.01% | 1761 |
|
|
2025
Q1 | $750K | Hold |
23,254
| – | – | ﹤0.01% | 1763 |
|
|
2024
Q4 | $841K | Hold |
23,254
| – | – | ﹤0.01% | 1776 |
|
|
2024
Q3 | $725K | Hold |
23,254
| – | – | ﹤0.01% | 1836 |
|
|
2024
Q2 | $622K | Sell |
23,254
-271
| -1% | -$7.86K | ﹤0.01% | 1874 |
|
|
2024
Q1 | $801K | Buy |
23,525
+2
| +0% | +$60 | ﹤0.01% | 1770 |
|
|
2023
Q4 | $680K | Sell |
23,523
-43
| -0.2% | -$1.14K | ﹤0.01% | 1849 |
|
|
2023
Q3 | $650K | Buy |
23,566
+3
| +0% | +$91 | ﹤0.01% | 1795 |
|
|
2023
Q2 | $708K | Sell |
23,563
-26
| -0.1% | -$910 | ﹤0.01% | 1791 |
|
|
2023
Q1 | $854K | Buy |
23,589
+12,894
| +121% | +$496K | ﹤0.01% | 1721 |
|
|
2022
Q4 | $381K | Sell |
10,695
-10,695
| -50% | -$372K | ﹤0.01% | 1859 |
|
|
2022
Q3 | $724K | Buy |
21,390
+10,707
| +100% | +$348K | ﹤0.01% | 1792 |
|
|
2022
Q2 | $309K | Sell |
10,683
-53,543
| -83% | -$1.53M | ﹤0.01% | 2060 |
|
|
2022
Q1 | $2.08M | Sell |
64,226
-17,395
| -21% | -$533K | ﹤0.01% | 1215 |
|
|
2021
Q4 | $2.38M | Buy |
81,621
+7,494
| +10% | +$227K | ﹤0.01% | 1221 |
|
|
2021
Q3 | $1.98M | Sell |
74,127
-12,983
| -15% | -$348K | ﹤0.01% | 1258 |
|
|
2021
Q2 | $2.68M | Sell |
87,110
-11,853
| -12% | -$363K | ﹤0.01% | 1188 |
|
|
2021
Q1 | $2.59M | Buy |
98,963
+24,620
| +33% | +$689K | ﹤0.01% | 1138 |
|
|
2020
Q4 | $1.87M | Buy |
74,343
+7,216
| +11% | +$155K | ﹤0.01% | 1134 |
|
|
2020
Q3 | $1.4M | Buy |
67,127
+5,512
| +9% | +$125K | ﹤0.01% | 1108 |
|
|
2020
Q2 | $1.46M | Buy |
61,615
+29,473
| +92% | +$651K | ﹤0.01% | 1076 |
|
|
2020
Q1 | $578K | Buy |
32,142
+1,695
| +6% | +$35.6K | ﹤0.01% | 1164 |
|
|
2019
Q4 | $722K | Sell |
30,447
-635,180
| -95% | -$15.4M | ﹤0.01% | 1262 |
|
|
2019
Q3 | $18.3M | Buy |
665,627
+5,107
| +0.8% | +$151K | 0.01% | 848 |
|
|
2019
Q2 | $21.9M | Sell |
660,520
-10,275
| -2% | -$352K | 0.01% | 774 |
|
|
2019
Q1 | $23.5M | Buy |
670,795
+29,949
| +5% | +$1.11M | 0.01% | 747 |
|
|
2018
Q4 | $21.3M | Sell |
640,846
-18,484
| -3% | -$795K | 0.01% | 734 |
|
|
2018
Q3 | $33.2M | Sell |
659,330
-6,062
| -0.9% | -$299K | 0.02% | 691 |
|
|
2018
Q2 | $39.8M | Buy |
665,392
+118,289
| +22% | +$6.13M | 0.02% | 618 |
|
|
2018
Q1 | $25.1M | Buy |
547,103
+123,082
| +29% | +$5.14M | 0.01% | 741 |
|
|
2017
Q4 | $16.9M | Buy |
424,021
+157,875
| +59% | +$6.24M | 0.01% | 785 |
|
|
2017
Q3 | $10.6M | Buy |
+266,146
| New | +$11.5M | 0.01% | 855 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Janus Henderson Group's SUPN Position: Q1 2026 in Review
Janus Henderson Group held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 23,254 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1617.
Janus Henderson Group first reported a position in SUPN in Q3 2017 and has held it in 35 quarters since. The position peaked at $39.8M in Q2 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Janus Henderson Group held 23,254 shares of Supernus Pharmaceuticals worth $1.2M as of Q1 2026.
- Janus Henderson Group left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
- Supernus Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1617 holding.
- Janus Henderson Group first reported a position in Supernus Pharmaceuticals in Q3 2017 and has held it in 35 quarters since.
- Janus Henderson Group's Supernus Pharmaceuticals position peaked at $39.8M in Q2 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.